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Abstract 
Background: Valved holding chambers (VHCs) are essential for efficient pulmonary delivery of inhaled 
medication in preschool children. The numerous devices on the market vary in material, aerodynamic 
characteristics, volume, valve properties, and mask design. Drug delivery is affected by the VHC 
characteristics as well as by the age and breathing pattern of the child.  
Methods: We measured the drug delivery efficacy of five VHCs widely available on the market, 
evaluated the effect of facemasks; and tested the differences between manufacturing lots. A breathing 
simulator was used to mimic normal (respiratory rate (RR) 25/min and tidal volume (VT) 200 mL) and 
obstructive (RR 50/min and VT 50 mL) breathing of infants and toddlers. 
Results: Salbutamol output was significantly higher with a normal breathing pattern compared to the 
obstructive breathing pattern in most VHCs. Without masks, the differences in the median in vitro filter 
doses of salbutamol were mainly from 2–10-fold among different types of VHCs. With masks, there was 
a greater than 20-fold difference in drug delivery capacity between the most and least effective devices. 
Most VHCs had a notable variation of performance between individual devices from different lots within 
the same brand. 
Conclusions: There was an extreme variation in the salbutamol delivery performance among different 
types of VHCs for both normal and obstructive pediatric breathing patterns with and without masks. This 
magnitude of performance variability can have significant and unpredictable clinical implications. 
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Introduction 
Acute wheezing with bronchoconstriction is most common before school age compared to any other age 
group1,2. Furthermore, acute exacerbations of asthma account for approximately 10 % of emergency visits 
in children and result in hospitalization of 20–40 % of cases3. Efficient pulmonary delivery of aerosolized 
medication is particularly challenging in preschool children due to their variable respiratory rate (RR) and 
low tidal volume (VT). 
The use of valved holding chambers (VHCs) improves drug delivery and precludes the need for the 
coordination of actuation-inhalation from a pressurized metered dose inhaler (pMDI)4,5. Facemasks (later 
referred to as masks) serve as a patient-device interface to facilitate drug delivery in children younger 
than four years and other patients who are incapable of holding a mouthpiece between the lips and teeth4. 
A tight, yet comfortable, mask-to-face seal is essential for reliable drug delivery6,7,8. Children from the 
age four years are generally able to use VHCs without masks4. 
Commercially available VHCs and masks differ in material, electrostatic and aerodynamic characteristics; 
volume; dead space; valve properties; and mask design. The behavior of an aerosolized drug depends on 
the VHC and mask used. Certain combinations of pMDI-VHC may result in drastic differences in dose 
output4,5,9,10,11,12,13. 
Studies evaluating drug delivery by VHCs have mainly been performed with inspiratory flow rates of 20–
60 L/min, and only a few have used rates below 10 L/min14,15,16. Nevertheless, drug delivery is dependent 
on the patient population since the breathing pattern, VT, peak inspiratory flow rate (PIFR), and resting 
RR all change with growth and development13,17,18,19. Tidal volume is approximately 7–10 mL/kg of ideal 
body weight19 in the first few years of life. With age, RR decreases while VT increases20. During 
bronchoconstriction, VT decreases and RR increases, and asthmatic patients have a higher range of 
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variation in PIFR compared to healthy subjects18. Operation of VHCs under suboptimal conditions is 
clinically important since children below school age can have inspiratory flow rates as low as 2 L/min18. 
A significant proportion of published studies evaluating and comparing the efficacy of VHCs are funded 
by their manufacturers, causing potential bias. 
VHCs play a significant role in the treatment of millions of children worldwide. At present, there are no 
universal standards specifically applicable to orally inhaled drug products. Regional guidelines (e.g., by 
the European Medical Agency (EMA), US Food and Drug Administration (FDA), the Chinese Food and 
Drug Administration and the Japanese Ministry of Health, Labour and Welfare) provide a list of 
parameters that are critical to the safety, quality and efficacy of the final product depending on the 
specific type of inhaled preparation concerned. It has been recognized that the amount of drug received by 
the patient using an add-on device with pMDI will be directly influenced by the inhalation profile and 
user in question21. 
To achieve a better understanding of how drug delivery is affected in different patient groups, test 
systems should reflect the physiology of the intended users, and the performance of a given pMDI should 
be tested with a particular VHC with and without masks22. The main goals of this study are to quantify 
the impact of VHCs in a clinically relevant way. When a mask is used, measurement of the emitted dose 
(ED) should be performed with an age specific face model that physiologically simulates accurate 
dimensions and facial tissue. In addition, the face model should be correctly aligned with the mask to 
mimic real life usage. An array of face models have been developed for this purpose, including the Sophia 
Anatomical Infant Nose-Throat (SAINT) model23, the family of Aerosol Delivery to an Anatomical 
Model (ADAM) face models24, and the Soft Anatomical Mask (SAM) models25. 
We recently reported marked differences in in vitro salbutamol delivery between two VHCs (Babyhaler, 
BH and Optichamber Diamond, OD) using numerous pediatric breathing patters13. Alarmingly, the drug 
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delivery capacity of BH, which is available on the market globally, was close to zero when measured with 
obstructive breathing patterns. There seems to be a risk for a very poor or unreliable drug delivery 
performance with some VHC models, especially in small children with bronchoconstriction (who have a 
very low VT and high RR). 
Our hypothesis was that the amount of salbutamol delivered through VHCs is affected by the design and 
material of the VHCs and their corresponding masks, causing significant differences between drug 
delivery efficacies among different available VHCs. We also hypothesized that the drug delivery efficacy 
may vary, even between individual VHCs of the same type. Therefore, the detailed aims of this study 
were: 1) to assess the drug delivery efficacy of five VHCs widely available on the market; 2) to evaluate 
the effect of masks; and 3) to test whether there are differences in drug delivery between individual 
devices of the same type from different manufacturing lots. As the breathing pattern has been shown to 
affect drug delivery13, we used two different breathing patterns that mimic the RR and VT of infants and 
small children during normal and obstructive breathing. 
6 
Materials and Methods 
Device setup 
Delivery of salbutamol sulphate generated by a pMDI (Ventoline Evohaler 1 mg/mL, GlaxoSmithKline 
Inc., Evreux, France) was measured in five types of VHCs with and without corresponding masks (table 
1). The mask for each VHC was selected based on the manufacturers’ recommendations. Three separate 
VHCs and masks from different manufacturing lots were used for each brand. Prior to each experiment, 
all the components of the VHCs were immersed in lukewarm water with detergent4 (Fairy Liquid, Proctor 
& Gamble, UK), rinsed under running tap water, and left to air-dry vertically.  
A previously validated horizontal test rig with a soft anatomical face model (SAM0)25 designed for the 
evaluation of VHC and mask performance was used (figure 1). Each VHC was positioned in its custom 
built cradle that could be fully adjusted to the optimal position. Each VHC-mask system was naturally 
applied against the face replica using a pulley system that delivered a constant force of 4.9 N26. 
A filter (PARI Respiratory Equipment, Inc., USA) within a low dead-space (10 mL) filter holder was 
used to trap drug particles. For measurements without masks (figure 1A), the filter holder was positioned 
between the mouthpiece of the VHC and the breathing simulator (Sinus Breathing Simulator; PARI, 
Starnberg, Germany). When a mask was used, the filter holder was connected to an airtight metal tube 
inside the “mouth” of the face model (figure 1B). The location of the filter within SAM0 was chosen 
based on previous work8. The simulator produced alternating inspirations and expirations with a 
sinusoidal wave and a duty cycle (inspiratory proportion of the breathing cycle) of 0.5. The accuracy of 
the breathing simulator was validated by a Fluke VT305 Gas Flow Analyzer (Fluke Biomedical, USA). 
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Measurement protocols 
We used two different clinically meaningful pediatric breathing patterns18 (table 2): RR 25/min with VT 
200 mL (normal breathing) and RR 50/min with VT 50 mL (obstructive breathing) for each VHC and 
VHC-mask combination. For every setup, the salbutamol output was measured on six replications using 
individual devices from three lots. 
Before each measurement sequence, pMDIs were primed by actuating them five times. Before every 
actuation, the pMDI was shaken vigorously five times. The pMDI was then inserted into the VHC and 
immediately actuated at the start of inhalation27. During each measurement, the valve movement was 
constantly assessed by visual inspection. Salbutamol was left to accumulate in the filter for eight 
breathing cycles, which has been shown to be sufficient to empty even larger volume VHCs4,26,27,28. The 
filters were sealed with Parafilm M (Bemis Company, Inc., Oshkosh, WI) until analysis of the drug 
content.  
Filter analysis 
Drug particles deposited on the filters in each measurement protocol were recovered and analyzed by 
high-performance liquid chromatography (HPLC) carried out by Emmace Consulting AB (Lund, 
Sweden). The HPLC method was based on the internal standard methodology, and the limit of 
quantitation (LOQ) was determined as the peak height corresponding to 10 times the noise level. The 
LOQ was 2 µg. The HPLC system (Agilent 1100) was fitted with the appropriate column (Symmetry 
[Waters], C18, 5 µm, 50x3.9 mm). Bracketing standards were generated and run, and the accuracy of the 
standards was checked. The standards were injected and run at least 6 times. The percentage relative 
standard deviation of the bracketing standards was < 2 % throughout the runs with excellent linearity 
(y=0.0021x, R2=0.9998). To assess how the results were affected by the possible variation in the output of 
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pMDIs, we measured the emitted dose of each pMDI used in the study six times by connecting a filter 
directly to the mouthpiece of the pMDI. The median dose of salbutamol sulphate measured directly from 
the mouthpiece of the pMDIs was close to the nominal dose, with only a minor variation overall (median 
92.0 µg, 95 % confidence interval (CI) 90.0–94.1 µg). 
Statistics 
On the basis of our previous study13, it was anticipated that six measurements for each device from each 
lot and 18 measurements for each VHC setup would allow the detection of possible significant 
differences. The data were not assumed to be normally distributed. The in vitro filter dose values are 
reported as the medians and minimum and maximum values. To test for pairwise differences in the in 
vitro filter dose values between different VHCs, setups and breathing patterns, the Mann-Whitney U test 
was used. To assess the difference between devices from three different lots, the Kruskal Wallis test was 
used. SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, N.Y., USA) was used for data 
analysis. 
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Results 
Figure 2, table 3 and table 4 illustrate the drug delivery performances of three individual VHCs from 
different manufacturing lots for each of the five VHC types both with and without their corresponding 
masks.  
Effect of the VHC type 
When masks were not used, the difference in the delivered median dose was most conspicuous between 
Vortex and BH (15-fold) and less prominent between OD and Aerochamber Plus (AP) (not significant) 
(table 4). Without masks, AP, OD and Vortex were clearly superior to A2A and BH. 
Effect of the mask 
Drug delivery was significantly poorer with masks for each VHC type, except for OD. The performances 
of A2A, BH and Vortex were extremely poor with masks, as drug delivery was reduced by 44–93 % 
(table 3). Only AP and OD were noticeably superior to the others when masks were used. With masks, 
OD delivered a significantly higher dose of salbutamol compared to any other VHC for both breathing 
patterns. When masks were used, the difference in the median in vitro filter dose of salbutamol was over 
20-fold, favoring OD over BH. 
Between-lot variation 
Most VHCs showed a notable variation of performance between individual devices from different lots. 
This between-lot variation was most prominent for BH and A2A (figure 2).  
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Consistency of results using two different respiratory patterns 
Salbutamol output was significantly higher with the normal breathing pattern (RR 25/min and VT 200 
mL) compared to the obstructive breathing pattern (RR 50/min and VT 50 mL) in all of the VHC models, 
except for BH without a mask and for Vortex with a mask (table 3). There were considerable differences 
in drug delivery between different VHC types for both respiratory patterns with and without masks (table 
4). 
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Discussion 
We found an extreme variation in the in vitro drug delivery performances of five VHCs with or without 
mask and even between similar devices from different manufacturing lots. Additionally, drug delivery 
was most often decreased by the use of a facemask or when applying a shallow and rapid respiratory 
pattern related to an airway obstruction. 
In line with previous studies14,29, we found that VHCs with a somewhat larger volume (i.e., A2A (210 
mL) and BH (350 mL)) had a significantly lower salbutamol output at low VT compared to smaller 
volume VHCs. On the other hand, Vortex (194 mL) performed significantly better than A2A without 
masks, despite having a similar volume. It has been speculated that the aerosol concentration and particle 
impaction in a larger volume VHC are less than those in a smaller volume VHC, which results in lower 
inhaled doses at a small VT but higher doses when the VHC can be emptied faster with a larger VT 17,29. 
However, chamber volume is not the only factor that affects drug delivery11,24. For example, Vortex and 
A2A have comparable chamber volumes but differed in almost every other aspect (e.g., shape, material, 
and valve design), any of which could be responsible for the recovered drug mass on the filter. 
We found that drug delivery was, in general, lower when a facemask was present using both respiratory 
patterns. This result is in line with findings from previous studies16. The lower drug delivery with masks 
and the variation between VHC-mask systems can be explained by the considerable differences in mask 
shape, volume and flexibility. The dead space and leak of the VHC-mask system have important 
implications. With the relatively large mask dead space (80 mL) of BH and its large chamber volume, 
only minimal amounts of drug would be delivered to the respiratory tract of infants with a low VT29. A2A 
has a similar mask dead space compared to BH, but its lower chamber volume could possibly explain its 
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higher drug output compared to BH. On the other hand, the filter dose of salbutamol was much lower 
using Vortex with a facemask present than without it. Since the dead space of this mask is relatively low, 
leakage of air between mask and the face model could explain the low amount of drug recovered from the 
filter 6,30,31. 
The degree of adaptability and flexibility of the mask are also important factors that influence the fit and 
mask-to-face seal as well as the physical dead space of the mask32. When pressed against the face, 
pressure causes compression of the mask, tightening the contact and reducing the actual mask dead 
space33,34. Thus, drug delivery will be affected by the force applied by the caregiver as well as the 
flexibility, compressibility and shape of the mask. A good seal with a minimal leak around the nose, 
cheeks, and mouth will ensure inspiration through the VHC and not allow ingress of ambient air between 
the mask and face6,7. 
Minh et al.26 investigated how children and their caregivers react to mask application force in 1–4 year-
old children. They found that the mask was best accepted when the mean mask application force was 
approximately 4 N. When the pressure against the face increases, children become agitated and a tight 
seal is difficult to maintain. With increasing discomfort, children are more likely to cry or scream, which 
also decreases the inhaled dose31,35. Shah et al.33 tested seven commonly used masks with various applied 
forces. Mask leakage was properly eliminated at a 6.7 N applied force, with only two out of the seven 
masks investigated, meaning that most masks require a higher application force, which will not always be 
accepted by children. Esposito-Festen et al.36 found that the lung dose decreased more rapidly when the 
mask leak was located close to the nose relative to a leak situated near the chin. Depending on the 
location and size of the mask leak, drug delivery can be very low, close to the limit of detection. In our 
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study, the mask fit to the anatomical face model considerably varied. We did not measure the degree of 
mask leak, but by visual inspection, the best seal appears to have been achieved by the OD mask. 
We are not aware of other studies reporting the between-lot variability of VHCs. Although we did not 
evaluate valve function, mechanical anomalies might explain our finding. Valves are fine structures in 
which even small inequalities may considerably affect their function especially at a low respiratory flow. 
Unfortunately, little is known about the minimum required flow rates needed by VHCs and VHC-mask 
systems to operate properly37. 
In most VHC models under investigation, a normal breathing pattern yielded a higher output dose 
compared to an obstructive breathing pattern. Drug delivery through VHCs has been shown to be 
dependent on the inhalation volume and flow13,32,38,39,40. Chavez and colleagues16 found that gradually 
increasing the VT from 36 mL to 290 mL led the filter dose of albuterol to increase in a logarithmic 
fashion with RRs of 12 L/min and 24 L/min, respectively. Similarly to our findings, Mitchell et al.10 
reported that some VHC designs yielded undetectable levels of salbutamol in challenging circumstances 
(RR 30/min with VT 50 mL). 
Our results are limited to the in vitro model used to compare the drug delivery efficacy of VHCs and 
masks. As we did not use an anatomical model of the airways or a cascade impactor but measured drug 
deposition right behind the oral cavity of the face model, we are over-estimating true pulmonary drug 
deposition and direct conclusions on pulmonary drug deposition in vivo cannot be made. However, the 
advantages of using an in vitro setting are the possibility to make multiple repeated measures and to avoid 
patient related sources of error, which allows the properties of the devices themselves to be focused on. In 
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addition, different predefined respiratory patterns can be tested in a repeatable manner between different 
device types. Further, our results only apply to the two breathing patterns tested. These quite reliably 
reflect VT and RR during normal and obstructive breathing in children between one and six years of age, 
but the VHCs might perform better in older children with a higher VT. In some children, application of a 
mask might result in irregular breathing with a sudden decrease or increase in inspiratory flow. Under 
experimental conditions, it is not possible to study all the potential combinations of breathing patterns. 
Certain breathing patterns are not present in the same child or in the same age group because masks are 
mainly used in children below 3–4 years of age. Nevertheless, the measured differences are consistent and 
the main conclusions remain the same. 
We used a respiratory simulator that produced a regular sinusoidal respiratory cycle instead of a random 
variable natural pattern in real subjects. Due to the sinusoidal pattern of respiratory cycle in our simulator, 
the duty cycle (proportion of inspiratory time of the whole respiratory cycle) was 0.5. This is not typical 
to humans and in young children duty cycle may be as low as 0.25. Therefore, although VT and RR in our 
study were comparable to real-life settings, the peak inspiratory flow differs from real breathing cycles in 
which the inspiratory proportion and curve shape differ from the experimental sinusoidal pattern.  
Although there were drastic differences in total drug delivery through the different types of VHCs, this 
may not reflect equal differences in actual pulmonary deposition in vivo. The in vitro filter dose 
represents the total dose of delivered drug particles regardless of their size. Pulmonary deposition and the 
clinical effect are influenced not only by the total dose but also by the particle size distribution of the 
aerosol delivered through the VHC. 
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In conclusion, there is a marked difference in in vitro drug delivery between different types of VHCs and 
their masks in normal and obstructive pediatric breathing patterns. Therefore, these devices cannot be 
regarded as interchangeable, and the recommended drug doses should be based on the properties of each 
VHC. Clinical trials are needed to test whether these differences in in vitro drug delivery also cause 
differences in treatment responses in vivo. 
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Figure 1. Setup to test drug delivery through different types of valved holding chambers (VHC) without face 
mask (A) and with face mask (B). To collect delivered salbutamol the filter (arrow) was placed between the VHC 
mouth piece and tubing to the breathing simulator when face mask was not used (A). When face mask was used, 
the filter (arrow) was placed behind the oral cavity of the anatomical face model (B) and the face mask was 
gently pressed against the face model by a pulley system creating a force of 4.9 N. 
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Figure 2. Drug delivery performance of five different types of valved holding chambers (VHC) with and without 
corresponding face masks. For each type of VHC, three individual devices from different manufacturing lots were 
used. Each box-plot represents six measurements using an individual device (middle thick line, median; box area, 
25-75th percentiles; upper and lower whiskers, minimum and maximum values; round dots, outliers).  P-values 
above bars are for the difference between ”no mask” and ”with mask” for each individual device, Mann-Whitney 
U test. P-values below groups of ”no mask” and ”with mask” are for the difference between lots within the group, 
Kruskal Wallis test. RR, respiratory rate. Vt, tidal volume. lot, manufacturing lot.
Table 1. Characteristics of the valved holding chambers 
VHC volume 
Chamber material 
and static chargea Valve characteristics and additional features 
Facemask 
volumeb 
A2A Spacer (A2A) 210 mL plastic, antistatic Internal circular unidirectional silicon valve, aerosol pass 
through the valve centrally 
80 mL 
Aerochamber plus (AP) 149 mL plastic, antistatic Internal circular unidirectional silicon valve, aerosol pass 
at the valve periphery, top outside inspiratory indicator 
46 mL 
Babyhaler (BH) 350 mL plastic, non-electrostatic Internal circular unidirectional silicon valve hinged 
centrally, aerosol pass at the valve periphery, additional 
top outside valve 
80 mL 
Optichamber diamond (OD) 140 mL plastic, antistatic Internal cone shaped unidirectional silicon valve, aerosol 
pass through the valve centrally, additional top outside 
expiratory valve 
45 mL 
Vortex 194 mL metal, reduced static charge Internal cone shaped unidirectional silicon valve, aerosol 
pass through the valve centrally 
46 mL 
aSpecified by the manufacturer 
bMask volume of the smallest available mask of each valved holding chamber (VHC). Measured by water displacement technique. 
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Table 2. Breathing patterns used and corresponding mean and peak inspiratory flows. 
Respiratory 
rate 
Tidal 
volume 
Minute ventilation 
(L/min) 
Mean inspiratory 
 flow (L/min) 
Peak inspiratory 
flow (L/min) 
Normal breathing 25/min 200 ml 5.0 10.0 15.7 
Obstructive  
breathing 50/min 50 ml 2.5 5.0 7.9 
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Table 3. Pairwise comparison of drug delivery between two types of breathing patterns for the same valved holding chambers brand. Results for each device type 
and setting represent 18 measurements pooled from six measurements on each three individual devices from three different lots. In vitro filter dose of salbutamol 
(µg) expressed as median (95% confidence interval, CI), RR 25/min with VT 200 ml represents normal breathing while RR 50/min with VT 50 ml represents 
obstructive breathing. 
No mask With mask Change in drug delivery 
when mask is used Median (95% CI) µg P-value Median (95% CI) µg P-value 
A2A Spacer, normal breathing 
A2A Spacer, obstructive breathing 
13.2 (11.3-15.3) 
10.0 (8.5-10.6)  0.040 
3.8 (3.2-4.2) 
2.6 (2.1-3.1)a < 0.001 
-71.2 % 
-74.0 % 
Aerochamber, normal breathing 
Aerochamber, obstructive breathing 
33.8 (31.8-40.6) 
15.5 (14.5-20.1) < 0.001 
21.5 (18.6-22.7)
5.2 (4.2-6.4) < 0.001 
-36.4 % 
-66.5 % 
Babyhaler, normal breathing 
Babyhaler, obstructive breathing 
3.2 (2.1-6.4)a 
2.6 (2.0-4.9)a 0.367 
1.8 (1.2-2.5)a 
0.2 (0.1-0.8)a < 0.001 
-43.8 % 
-92.3 % 
Optichamber, normal breathing 
Optichamber, obstructive breathing 
37.5 (35.0-42.7) 
24.6 (22.6-29.9) < 0.001 
43.0 (37.8-45.3)
20.5 (19.2-25.7) < 0.001 
+14.7 % 
-16.7 % 
Vortex, normal breathing 
Vortex, obstructive breathing 
46.9 (42.6-51.0) 
21.1 (20.9-23.0) < 0.001 
3.1 (1.2-3.8)a 
2.0 (1.6-2.3)a 0.150 
-93.4 % 
-90.5 % 
Values in bold = VHC with statistically significantly higher drug delivery in the pairwise comparison. 
P-values, Mann-Whitney U test. aSome values are below the limit of quantification (LOQ). 
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Table 4. Pairwise comparison of drug delivery between different types of valved holding chambers. Results for each device type and setting represent 18 
measurements pooled from six measurements on all three individual devices from three different lots. In vitro filter dose of salbutamol (µg) expressed as median 
(95% confidence interval, CI). 
Normal breathing (RR 25/min, VT 200 ml) Obstructive breathing (RR 50/min, VT 50 ml) 
No mask With mask No mask With mask 
Median 
(95% CI) µg P-value 
Median 
(95% CI) µg P-value 
Median 
(95% CI) µg P-value 
Median 
(95% CI) µg P-value 
A2A Spacer 
Aerochamber plus 
13.2 (11.3-15.3) 
33.8 (31.8-40.6) < 0.001 
3.8 (3.2-4.2) 
21.5 (18.6-22.7) < 0.001
10.0 (8.5-10.6) 
15.5 (14.5-20.1) < 0.001 
2.6 (2.1-3.1)a
5.2 (4.2-6.4) < 0.001 
A2A Spacer 
Babyhaler 
13.2 (11.3-15.3) 
3.2 (2.1-6.4)a < 0.001 
3.8 (3.2-4.2)
1.8 (1.2-2.5)a < 0.001 
10.0 (8.5-10.6) 
2.6 (2.0-4.9)a < 0.001 
2.6 (2.1-3.1)a
0.2 (0.1-0.8)a < 0.001 
A2A Spacer 
Optichamber diamond 
13.2 (11.3-15.3) 
37.5 (35.0-42.7) < 0.001 
3.8 (3.2-4.2) 
43.0 (37.8-45.3) < 0.001
10.0 (8.5-10.6) 
24.6 (22.6-29.9) < 0.001 
2.6 (2.1-3.1)a 
20.5 (19.2-25.7) < 0.001
A2A Spacer 
Vortex 
13.2 (11.3-15.3) 
46.9 (42.6-51.0) < 0.001 
3.8 (3.2-4.2)
3.1 (1.2-3.8)a 0.018 
10.0 (8.5-10.6) 
21.1 (20.9-23.0) < 0.001 
2.6 (2.1-3.1)
2.0 (1.6-2.3)a 0.012 
Aerochamber plus 
Babyhaler 
33.8 (31.8-40.6) 
3.2 (2.1-6.4)a < 0.001 
21.5 (18.6-22.7)
1.8 (1.2-2.5)a < 0.001 
15.5 (14.5-20.1) 
2.6 (2.0-4.9)a < 0.001 
5.2 (4.2-6.4)
0.2 (0.1-0.8)a < 0.001 
Aerochamber plus 
Optichamber diamond 
33.8 (31.8-40.6) 
37.5 (35.0-42.7) 0.076
21.5 (18.6-22.7) 
43.0 (37.8-45.3) < 0.001
15.5 (14.5-20.1) 
24.6 (22.6-29.9) < 0.001 
5.2 (4.2-6.4) 
20.5 (19.2-25.7) < 0.001
Aerochamber plus 
Vortex 
33.8 (31.8-40.6) 
46.9 (42.6-51.0) < 0.001 
21.5 (18.6-22.7)
3.1 (1.2-3.8)a < 0.001 
15.5 (14.5-20.1) 
21.1 (20.9-23.0) < 0.001 
5.2 (4.2-6.4)
2.0 (1.6-2.3)a < 0.001 
Babyhaler 
Optichamber diamond 
3.2 (2.1-6.4)a 
37.5 (35.0-42.7) < 0.001 
1.8 (1.2-2.5)a 
43.0 (37.8-45.3) < 0.001
2.6 (2.0-4.9)a 
24.6 (22.6-29.9) < 0.001 
0.2 (0.1-0.8)a 
20.5 (19.2-25.7) < 0.001
Babyhaler 
Vortex 
3.2 (2.1-6.4)a 
46.9 (42.6-51.0) < 0.001 
1.8 (1.2-2.5)a
3.1 (1.2-3.8)a 0.200 
2.6 (2.0-4.9)a 
21.1 (20.9-23.0) < 0.001 
0.2 (0.1-0.8)a
2.0 (1.6-2.3)a < 0.001 
Optichamber diamond 
Vortex 
37.5 (35.0-42.7) 
46.9 (42.6-51.0) < 0.001 
43.0 (37.8-45.3)
3.1 (1.2-3.8)a < 0.001 
24.6 (22.6-29.9) 
21.1 (20.9-23.0) 0.004
20.5 (19.2-25.7) 
2.0 (1.6-2.3)a < 0.001 
Values in bold = VHC with statistically significantly higher drug delivery in the pairwise comparison. P-values, Mann-Whitney U test. 
aSome values are below the limit of quantification (LOQ). 
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